Premium
Breast‐Cancer Diagnosis by Neuropeptide Y Analogues: From Synthesis to Clinical Application
Author(s) -
Khan Irfan U.,
Zwanziger Denise,
Böhme Ilka,
Javed Muhammad,
Naseer Hamid,
Hyder Syed W.,
BeckSickinger Annette G.
Publication year - 2010
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.200905008
Subject(s) - neuropeptide y receptor , breast cancer , cancer , neuropeptide , receptor , cancer research , transduction (biophysics) , peptide , chemistry , medicine , computational biology , endocrinology , biology , biochemistry
Selective, sensitive, and specific breast cancer diagnosis : Neuropeptide Y (NPY) and the Y 1 R‐selective [Phe 7 , Pro 34 ]NPY peptide were labeled with Re/ 99m Tc and pre‐clinically characterized using competition receptor binding and signal transduction assays, and also microscopic, metabolic‐stability, rabbit body‐uptake, and protein‐binding studies. Selective uptake of the 99m Tc(core) 3+ ‐(N α His‐ac)‐labeled [Phe 7 , Pro 34 ]NPY analogue in human breast‐cancer patients was obtained by whole body scintimammography.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom